In recent weeks, the Asian markets have shown resilience amidst global economic uncertainties, with Chinese stocks seeing a rise due to hopes for more stimulus in response to persistent deflation. As investors navigate these fluctuating conditions, identifying stocks that may be trading below their estimated value can offer potential opportunities for those looking to capitalize on market inefficiencies.
Name
Current Price
Fair Value (Est)
Discount (Est)
SILICON2 (KOSDAQ:A257720)
₩52800.00
₩104187.44
49.3%
Range Intelligent Computing Technology Group (SZSE:300442)
CN¥52.55
CN¥103.62
49.3%
Peijia Medical (SEHK:9996)
HK$7.93
HK$15.57
49.1%
Nanya New Material TechnologyLtd (SHSE:688519)
CN¥42.94
CN¥85.38
49.7%
Medy-Tox (KOSDAQ:A086900)
₩162200.00
₩322233.66
49.7%
Mandom (TSE:4917)
¥1419.00
¥2835.57
50%
Livero (TSE:9245)
¥1727.00
¥3430.34
49.7%
Hugel (KOSDAQ:A145020)
₩355000.00
₩698441.84
49.2%
HL Holdings (KOSE:A060980)
₩41500.00
₩82181.95
49.5%
ALUX (KOSDAQ:A475580)
₩11500.00
₩22593.59
49.1%
Let’s review some notable picks from our screened stocks.
Overview: ISU Petasys Co., Ltd. manufactures and sells printed circuit boards (PCBs) globally, with a market capitalization of approximately ₩4.43 trillion.
Operations: The company’s revenue primarily comes from the manufacture and sale of printed circuit boards, amounting to approximately ₩889.75 billion.
Estimated Discount To Fair Value: 26%
ISU Petasys is trading at ₩60,400, 26% below its estimated fair value of ₩81,676.04. Despite recent shareholder dilution and high debt levels, the company shows promising growth prospects with forecasted earnings growth of 28.4% per year and revenue growth of 18.3% per year, both surpassing the Korean market averages. However, its share price has been highly volatile recently, which may concern some investors focusing on stability.
KOSE:A007660 Discounted Cash Flow as at Jul 2025
Overview: Hanmi Pharm Co., Ltd. is a biopharmaceutical company involved in the manufacture and sale of pharmaceutical products across South Korea, China, Japan, the United States, and other international markets, with a market cap of ₩3.75 trillion.
Operations: The company’s revenue segments consist of Medicine at ₩1.13 trillion, Overseas Medicine at ₩354.39 billion, and Raw Drug Substance at ₩106.89 billion.
Story Continues
Estimated Discount To Fair Value: 39.4%
Hanmi Pharm is trading at ₩296,000, significantly below its estimated fair value of ₩488,229.59, indicating a potential undervaluation. The company anticipates robust earnings growth of 21.8% annually over the next three years, outpacing the Korean market’s average. Despite a lower forecasted return on equity of 13.9%, Hanmi Pharm’s revenue is expected to grow faster than the market at 8.4% per year, supporting its strong cash flow position amidst recent earnings fluctuations.
KOSE:A128940 Discounted Cash Flow as at Jul 2025
Overview: GMO Internet Group, Inc. offers a range of internet services globally and has a market capitalization of approximately ¥378.28 billion.
Operations: The company’s revenue segments include Internet Infrastructure, Online Advertising & Media, Internet Finance, and Cryptoassets.
Estimated Discount To Fair Value: 41.1%
GMO Internet Group is trading at ¥3,719, significantly below its estimated fair value of ¥6,316.09, highlighting a potential undervaluation. The company’s earnings are projected to grow at 16.9% annually, surpassing the Japanese market’s average growth rate of 7.7%. Additionally, revenue growth is expected to outpace the market at 7.9% per year. Recent buybacks and dividend increases reflect a commitment to shareholder returns while maintaining strong cash flow management amidst moderate profit growth expectations.
TSE:9449 Discounted Cash Flow as at Jul 2025
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include KOSE:A007660 KOSE:A128940 and TSE:9449.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com